SALCS 2022 | Emerging cell therapies for liver cancer

Mitchell Ho, PhD, National Institutes of Health, Bethesda, MD, provides an overview of the latest developments in novel cell therapies for liver cancer, including natural killer (NK) cell therapy and universal CARs. Current challenges in developing NK cell therapies include issues with persistence and potential resistance. GPC3 has additionally been identified as a potential target for these emerging immunotherapies. This interview took place at the 2022 San Antonio Liver Cancer Symposium (SALCS) in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.